Normal haemostasis depends on an intricate balance between mechanisms of bleeding and mechanisms of thrombosis, and this balance can be altered after traumatic brain injury (TBI). Impaired haemostasis could exacerbate the primary insult with risk of initiation or aggravation of bleeding; anticoagulant use at the time of injury can also contribute to bleeding risk after TBI. Many patients with TBI have abnormalities on conventional coagulation tests at admission to the emergency department, and the presence of coagulopathy is associated with increased morbidity and mortality. Further blood testing often reveals a range of changes affecting platelet numbers and function, procoagulant or anticoagulant factors, fibrinolysis, and interactions between the coagulation system and the vascular endothelium, brain tissue, inflammatory mechanisms, and blood flow dynamics. However, the degree to which these coagulation abnormalities affect TBI outcomes and whether they are modifiable risk factors are not known. Although the main challenge for management is to address the risk of hypocoagulopathy with prolonged bleeding and progression of haemorrhagic lesions, the risk of hypercoagulopathy with an increased prothrombotic tendency also warrants consideration.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/S1474-4422(17)30197-7 | DOI Listing |
Wearable Technol
December 2024
Department of Mechanical Engineering, Vanderbilt University, Nashville, TN, USA.
This work studies upper-limb impairment resulting from stroke or traumatic brain injury and presents a simple technological solution for a subset of patients: a soft, active stretching aid for at-home use. To better understand the issues associated with existing associated rehabilitation devices, customer discovery conversations were conducted with 153 people in the healthcare ecosystem (60 patients, 30 caregivers, and 63 medical providers). These patients fell into two populations: spastic (stiff, clenched hands) and flaccid (limp hands).
View Article and Find Full Text PDFChronic Stress (Thousand Oaks)
January 2025
Brain Research and Innovation Centre, Ministry of Defence, Utrecht, the Netherlands.
Background: Trauma-focused psychotherapy is treatment of choice for post-traumatic stress disorder (PTSD). However, about half of patients do not respond. Recently, there is increased interest in brain criticality, which assesses the phase transition between order and disorder in brain activity.
View Article and Find Full Text PDFACS Med Chem Lett
January 2025
Usona Institute, Fitchburg, Wisconsin 53711-5300, United States.
Innovations in pharmaceutical science drive new treatment approaches for cancer and brain injury. This Patent Highlight reviews findings from three patents focused on kinase inhibition in cancer therapy and using biomarkers to assess brain injury. By targeting key enzymes such as AKT1 and diacylglycerol kinase alpha (DGKα), these innovations offer new strategies for cancer treatment, particularly in cases of resistance to conventional therapies.
View Article and Find Full Text PDFInt J Crit Illn Inj Sci
December 2024
Department of Pediatrics, University College of Medical Sciences and Guru Teg Bahadur Hospital, Delhi, India.
Over the past three decades, awareness regarding pain management in neonates has risen significantly. It has been very well established that neonates can perceive, feel, and react to stimuli that cause pain and discomfort to them. Neonates admitted to neonatal intensive care units (NICUs) are repeatedly subjected to invasive treatments, most of which are painful.
View Article and Find Full Text PDFNeuropsychiatr Dis Treat
January 2025
Department of Neurosurgery, Changzhi People's Hospital, Changzhi, Shanxi Province, People's Republic of China.
Background: Resolvin D2 (RvD2), which exhibits anti-inflammatory properties, is neuroprotective. This study aimed to ascertain the potential of serum RvD2 level as a prognostic predictor of moderate-to-severe traumatic brain injury (msTBI).
Methods: In this prospective cohort study, serum RvD2 levels were measured in 136 patients with msTBI and 100 healthy controls.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!